Peter C. Adamson
彼得·亚当森
MD
Professor of Pediatrics and Pharmacology; Former Chair, Children's Oncology Group (COG)儿科学与药理学教授，儿童肿瘤组前主席
👥Biography 个人简介
Peter C. Adamson, MD is a preeminent figure in pediatric oncology drug development and clinical trial infrastructure. As long-time Chair of the Children's Oncology Group (COG)—the world's largest organization devoted exclusively to childhood and adolescent cancer research—he oversaw the conduct of over 100 open clinical trials spanning 200+ member institutions in North America, Australia, New Zealand, and Europe. His scientific work has focused on the pharmacokinetics and pharmacodynamics of anticancer agents in children, including key studies on dosing of imatinib, crizotinib, and HDAC inhibitors in pediatric populations. He has been a leading voice in advocating for regulatory reform that requires pediatric evaluation of new oncology drugs, contributing to the development of the FDA's Pediatric Research Equity Act provisions and the Pediatric Cancer Research and Access Act.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Leadership of Children's Oncology Group
Served as Chair of COG from 2003 to 2016, expanding the network to more than 200 member institutions and orchestrating a portfolio of trials that advanced care for virtually every type of childhood cancer, including landmark studies in ALL, Wilms tumor, osteosarcoma, and pediatric solid tumors.
Pediatric Drug Development and Regulatory Advocacy
Led efforts to ensure that new oncology drugs receive pediatric evaluation, contributing to policy frameworks including the Pediatric Research Equity Act and FDA pediatric labeling guidance, and serving as an advisor to the FDA Oncologic Drugs Advisory Committee.
Pharmacokinetics of Targeted Agents in Children
Conducted definitive PK/PD studies for pediatric dosing of imatinib, crizotinib, and multiple HDAC inhibitors, establishing age-appropriate dosing regimens that underpin global pediatric treatment protocols.
Global Pediatric Oncology Harmonization
Co-led the Pediatric Oncology in Developing Countries (PODC) working group and fostered harmonization of COG protocols with SIOP and other international cooperative groups, enabling global data sharing and joint trial conduct.
Representative Works 代表性著作
Pediatric oncology: the evolution from empiricism to targeted therapy
New England Journal of Medicine (2014)
Seminal perspective on the transformation of pediatric oncology from empirical cytotoxic chemotherapy toward molecularly guided treatment, reviewing lessons from adult precision oncology and the challenges unique to childhood malignancies.
Imatinib pharmacokinetics in children and adults with Philadelphia chromosome-positive leukemia
Clinical Cancer Research (2009)
Definitive study establishing weight-based dosing for imatinib in children that achieves exposures equivalent to the approved adult dose, informing COG AALL0031 and successor protocols.
Challenges in the development of new agents for pediatric cancers
Journal of Clinical Oncology (2018)
Analysis of barriers specific to new drug development in pediatric oncology including small population size, disease heterogeneity, and regulatory incentive alignment.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-04-06 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 彼得·亚当森 的研究动态
Follow Peter C. Adamson's research updates
留下邮箱，当我们发布与 Peter C. Adamson（University of Pennsylvania / Formerly Children's Hospital of Philadelphia）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment